Biocom California Selects New Chair for its Board of Directors

SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)-- Biocom, the association representing the California life science industry, today announced that it has named a new board chair and chair elect. Timothy Scott, CEO of TEGA Therapeutics is the new chair, and Sabrina Martucci Johnson, CEO of Daré Bioscience, is the chair elect.

“These board leadership positions are crucial for shaping Biocom California’s goals and implementing new programs,” said Joe Panetta, president and CEO of Biocom California. “Tim and Sabrina both bring a passion for the life science industry to these roles and have already shown themselves to be capable leaders during their respective tenures as officers of our board.”

Mr. Scott is co-founder and CEO of TEGA Therapeutics, a glycobiology company focused on recombinant heparin and heparan sulfates, and lysosomal storage disorders. He previously was co-founder and President of Pharmatek Laboratories, a contract development and manufacturing company. Mr. Scott serves on the Board of Avelas, a bioscience company working to create better outcomes for cancer patients with its activatable cell-penetrating peptide technology. He also serves on the board of DTx, a biotechnology company using fatty acid motifs to deliver RNA therapeutics. Mr. Scott is immediate past Executive Board Chair of CONNECT, a non-profit organization helping to create and scale innovation companies in San Diego. He also served as Chair of the Biocom COVID-19 Task Force. Mr. Scott serves on the Medical Research Advisory Committee for the Conrad Prebys Foundation, providing grants to innovative research in the health sciences. At UC San Diego, he serves on the Dean’s Advisory Council for the Division of Biological Sciences. In the community, Mr. Scott is a trustee for the La Jolla Playhouse, a Tony-award winning regional theatre. And he serves on the board of Outside the Lens, a non-profit providing photography and digital media programs for underserved youth. Mr. Scott earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.

Ms. Johnson is founder, president and CEO of Daré Bioscience, a leader in women’s health innovation. Previously, Ms. Johnson served as president of WomanCare Global Trading, a specialty pharmaceutical company in female reproductive healthcare with commercial product distribution in over 100 countries. Prior to that, Ms. Johnson served as CFO of Cypress Bioscience, a publicly-traded pharmaceutical company, and in addition served as its COO. Ms. Johnson began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on their recombinant factor VIII program, and later held marketing and sales positions with Advanced Tissue Sciences and Clonetics Corporation. Ms. Johnson currently serves on the boards of directors of ATAI Life Sciences, a publicly-traded clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders; Aethlon Medical, a publicly-traded company developing immunotherapeutic technologies to combat infectious disease and cancer; and the Clearity Foundation as past board chair. Additionally, Ms. Johnson serves on the board of advisors of Tulane University School of Science & Engineering and on the audit committee of Project Concern International.

In addition to announcing the new chair and chair elect, Biocom California also named the remainder of its board officers, who are as follows:

• Vice chair, professional services: Carin Canale-Theakston, Canale Communications
• Vice chair, DE&I: Bernard Parker, Caligen Bio, LLC
• General counsel: Lisa Haile, J.D., Ph.D., DLA Piper
• Treasurer: Daniel Kleeburg, Ernst & Young
• Secretary: Stephen Ferruolo, J.D., Ph.D., Perkins Coie
• President and CEO: Joseph Panetta, Biocom California

About Biocom California

Biocom California is the leader and advocate for California’s life science sector. We work on behalf of more than 1,500 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs.

Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.

For more information on Biocom California, please visit our website at www.biocom.org. Connect with us on LinkedIn, Facebook, and Twitter (@BIOCOMCA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005058/en/